Navigation Links
Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections
Date:6/30/2009

SAN DIEGO, June 30 /PRNewswire/ -- Calixa Therapeutics Inc. today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in vitro and in vivo activity against Pseudomonas aeruginosa, including drug resistant isolates. Calixa is investigating CXA-101 as a potential treatment for serious bacterial infections in hospitalized patients.

The multi-center, randomized study is anticipated to enroll approximately 120 patients and will compare the efficacy and safety of CXA-101 with the current standard of therapy. The primary efficacy endpoint for this study is microbiological outcome at the test-of-cure visit between six to nine days after the end of therapy.

"The preclinical and Phase 1 results to date are very promising and indicate that CXA-101 is well tolerated and has broad-spectrum antibacterial coverage, including potent activity against increasingly resistant gram-negative pathogens such as Pseudomonas aeruginosa," said Dr. Ian Friedland, chief medical officer of Calixa. "We are going to present comprehensive preclinical and Phase 1 data at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy in September and other medical conferences. This Phase 2 study will generate important information on the safety and effectiveness of CXA-101 in complicated urinary tract infections, which are usually caused by gram-negative pathogens".

Eckard Weber, president and chief executive officer of Calixa and partner at the venture capital firm Domain Associates, LLC said, "With the continually increasing incidence of serious and life-threatening infections caused by resistant gram-negative bacteria and the paucity of new drugs in the pipeline to counter such resistance, we are working diligently to expedite the development of CXA-101. We are fully committed to providing patients and physicians with a much needed option for the treatment of life-threatening infections caused by gram-negative bacteria."

About Calixa Therapeutics

Calixa Therapeutics Inc. is a biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of infectious diseases. The company's initial focus is on developing novel antibiotics for use in the hospital setting. Calixa Therapeutics, which is privately held, is headquartered in San Diego and has operations in the San Francisco Bay Area. For additional information, please visit: www.calixainc.com.

    Contacts:
    Robert Flamm, Ph.D., or David Schull
    Russo Partners
    (212) 845-4226
    robert.flamm@russopartnersllc.com
    david.schull@russopartnersllc.com

    Eckard Weber, M.D.
    Calixa Therapeutics Inc.
    (858) 480-2420
    stone@domainvc.com

'/>"/>
SOURCE Calixa Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
2. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
3. Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
4. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
5. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
6. Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
7. Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
8. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
9. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
10. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
11. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
(Date:4/18/2017)... MINNEAPOLIS , April 18, 2017 Cogentix ... focused on providing the Urology, Uro/Gyn and Gynecology markets ... for the first quarter ended March 31, 2017 after ... The Company will host a conference call ... day on Tuesday, May 2, 2017 at 4:30 p.m. ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., developer ... series to be presented at the 2017 National Kidney ... today and continues through April 22. Physicians will present ... used to assess risk for acute kidney injury (AKI) ... failure (ADHF). Elevated levels of TIMP-2 ...
Breaking Medicine Technology:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... Phytomer USA ... As a Phytomer Account Manager, Smith’s role is to provide excellent customer ... that make up The Phytomer Group. Smith comes to Phytomer with a wealth of ...
(Date:4/28/2017)... ... April 28, 2017 , ... The National Campaign to ... the Access to Contraception for Women Servicemembers and Dependents Act of 2017. The ... will help to ensure that all members of the Armed Forces receive high ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of New Jersey ... “A” and its outlook as “stable.” At the same time, the ratings agency cautioned ... recent years, dip below “capital adequacy” thresholds required for its strong rating. , “Horizon ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Radiology Business Management ... officers for 2017-2018. The annual board election process has been in place since the ... , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... liability could substantially improve drug safety and minimize the cost of development. In ... ion channel inhibition using cell lines and for cardiac toxicity using induced pluripotent ...
Breaking Medicine News(10 mins):